sur B.R.A.I.N. Biotechnology Research And Information Network AG (isin : DE0005203947)
BRAIN Biotech AG Refocuses on Profitable Growth
BRAIN Biotech AG is sharpening its focus on profitable growth by launching a new segment, BRAINBiocatalysts, to drive expansion. This initiative combines the BioProducts and BioScience Zwingenberg segments. The company aims to achieve EUR 100 million revenue and a 15% adjusted EBITDA margin in the next five years. Strategic moves, including collaborations with Royalty Pharma and Akribion Therapeutics, have improved liquidity and earnings.
The company is confident in its enzyme business's future, supported by a strong science foundation. CEO Adriaan Moelker emphasizes opportunities from bundling production and research activities. The BRAINBioIncubator sector also offers substantial potential through project commercializations.
With a focus on sustainable, profitable growth, CFO Michael Schneiders notes that the new segment strengthens their valuation. BRAIN Biotech anticipates significant positive impacts on sales and EBITDA through these strategic initiatives.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de B.R.A.I.N. Biotechnology Research And Information Network AG